Looming patent cliffs and shrivelling pipelines have pharma's big players looking for new business models that will allow them to increase their bottom lines.
Bringing drug discovery into focus
GSK’s Anne Phillips offers a clear picture of transparency, bringing benefits to patients and the challenges of carrying out clinical trials in a global environment.
Trials and tribulations
Boehringer Ingelheim’s John Smith tells NGP about the importance of accountability in the pharmaceutical industry and the responsibilities of behaviour when a trial doesn’t quite go exactly to plan.
Economies of Scales
The benefits of essential fatty acids have long been established, but introducing them into the pharmaceutical sphere is a relatively recent phenomenon. Hilda Steineger explains how Pronova’s use of omega-3 from fish oil has transformed an age-old remedy into a potential blockbuster.
A limited shelf life?
Will President Obama’s healthcare reforms scuttle plans by pharmaceutical companies to combat patent expiries by switching branded products to OTC? Schering-Plough’s Brent Saunders brings NGP’s Natalie Brandweiner up to speed.
Joining forces
The terms Lean and Six Sigma have been used in pharmaceutical manufacturing for a number of years. Now there’s a new concept on the block that melds the two. Bayer’s Edgar Sur fills us in.
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.